pirfenidone has been researched along with sorafenib in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Groothuis, GM; Olinga, P; Oosterhuis, D; Westra, IM | 1 |
Cai, M; Chen, J; Chen, Y; Guo, Y; Huang, J; Huang, W; Lai, M; Liang, L; Lin, L; Liu, M; Xie, L; Zhang, X; Zhang, Y; Zhu, K | 1 |
2 other study(ies) available for pirfenidone and sorafenib
Article | Year |
---|---|
Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs.
Topics: Animals; Becaplermin; Benzamides; Benzylisoquinolines; Cinnamates; Collagen Type I; Connective Tissue Growth Factor; Depsides; Down-Regulation; Gene Expression; HSP47 Heat-Shock Proteins; Imatinib Mesylate; Liver; Liver Cirrhosis; Male; Models, Biological; Niacinamide; Organ Culture Techniques; Perindopril; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-sis; Pyridones; Pyrimidines; Rats; Rats, Wistar; Rosmarinic Acid; Sorafenib; Transforming Growth Factor beta1; Valproic Acid | 2014 |
Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Hyaluronoglucosaminidase; Liver Neoplasms; Lung Neoplasms; Signal Transduction; Sorafenib; Tumor Microenvironment | 2023 |